JP2007512844A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512844A5 JP2007512844A5 JP2006542782A JP2006542782A JP2007512844A5 JP 2007512844 A5 JP2007512844 A5 JP 2007512844A5 JP 2006542782 A JP2006542782 A JP 2006542782A JP 2006542782 A JP2006542782 A JP 2006542782A JP 2007512844 A5 JP2007512844 A5 JP 2007512844A5
- Authority
- JP
- Japan
- Prior art keywords
- ksr
- cancer
- expression
- composition
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000749825 Homo sapiens Connector enhancer of kinase suppressor of ras 1 Proteins 0.000 claims 31
- 101001137642 Homo sapiens Kinase suppressor of Ras 1 Proteins 0.000 claims 31
- 108091034117 Oligonucleotide Proteins 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 23
- 230000000295 complement effect Effects 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 241000124008 Mammalia Species 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 108010003046 KSR-1 protein kinase Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 3
- 108020004511 Recombinant DNA Proteins 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/727,358 US7301017B2 (en) | 2002-05-30 | 2003-12-03 | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| US10/727,358 | 2003-12-03 | ||
| PCT/US2004/040506 WO2005056756A2 (en) | 2003-12-03 | 2004-12-03 | Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007512844A JP2007512844A (ja) | 2007-05-24 |
| JP2007512844A5 true JP2007512844A5 (https=) | 2008-01-17 |
| JP4855265B2 JP4855265B2 (ja) | 2012-01-18 |
Family
ID=34677113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006542782A Expired - Fee Related JP4855265B2 (ja) | 2003-12-03 | 2004-12-03 | Ｒａｓ媒介性腫瘍形成の治療のためのｒａｓ不活性化のキナーゼサプレッサー |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7301017B2 (https=) |
| EP (1) | EP1697498B1 (https=) |
| JP (1) | JP4855265B2 (https=) |
| AT (1) | ATE457351T1 (https=) |
| AU (1) | AU2004297594B2 (https=) |
| CA (1) | CA2549384A1 (https=) |
| DE (1) | DE602004025499D1 (https=) |
| WO (1) | WO2005056756A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301017B2 (en) * | 2002-05-30 | 2007-11-27 | Kolesnick Richard N | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| US8927598B2 (en) * | 2008-01-30 | 2015-01-06 | Duke University | Treating oncogenic Ras driven cancers |
| WO2009137807A2 (en) * | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| CA2768042C (en) * | 2009-07-24 | 2017-11-21 | Universite De Montreal | Bret-based biosensors and methods for monitoring raf dimerization |
| US8900845B2 (en) | 2011-02-08 | 2014-12-02 | Washington University | Methods and uses of KSR kinase, and mutations thereof |
| US9526709B2 (en) * | 2011-04-06 | 2016-12-27 | Chemo-Enhanced Llc | Compositions and methods for treating cancer |
| US9968570B2 (en) | 2013-01-14 | 2018-05-15 | Chemo-Enhanced Llc | Compositions and methods for treating cancer |
| ES2879287T3 (es) * | 2015-09-15 | 2021-11-22 | Us Health | Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8 |
| KR101881874B1 (ko) * | 2016-04-29 | 2018-07-26 | 한국수력원자력 주식회사 | 저선량 방사선 조사에 의한 암화 예방 방법 |
| KR101875111B1 (ko) * | 2016-04-29 | 2018-07-09 | 한국수력원자력 주식회사 | 저선량 방사선을 이용한 암화유전자 Ras-유도 악성 암화 억제 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US591721A (en) | 1897-10-12 | Fan attachment | ||
| US4016043A (en) * | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US6261834B1 (en) * | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
| WO1994004672A1 (en) * | 1992-08-26 | 1994-03-03 | Dnx Corp. | Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals |
| US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5792638A (en) * | 1994-05-24 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Human ras-related oncogenes unmasked by expression cDNA cloning |
| US5591721A (en) * | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5700675A (en) * | 1995-12-13 | 1997-12-23 | Regents Of The University Of California | Protein kinase required for Ras signal transduction |
| US5786213A (en) * | 1996-04-18 | 1998-07-28 | Board Of Regents, The University Of Texas System | Inhibition of endogenous gastrin expression for treatment of colorectal cancer |
| GB9620749D0 (en) * | 1996-10-04 | 1996-11-20 | Brax Genomics Ltd | Identifying antisense oligonucleotides |
| EP0943013A2 (en) * | 1996-12-06 | 1999-09-22 | Niels Pallisgaard | Detection of chromosomal abnormalities |
| AU8280798A (en) * | 1997-07-03 | 1999-01-25 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
| US6849334B2 (en) | 2001-08-17 | 2005-02-01 | Neophotonics Corporation | Optical materials and optical devices |
| GB2335035B (en) * | 1998-03-03 | 2003-05-28 | Brax Genomics Ltd | Screening for functional antisense agents |
| WO2001047944A2 (en) * | 1999-12-28 | 2001-07-05 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| US6329203B1 (en) * | 2000-09-08 | 2001-12-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of glioma-associated oncogene-1 expression |
| US20030051267A1 (en) * | 2001-05-10 | 2003-03-13 | Pfizer Inc. | Targeted disruption of kinase suppressor of RAS |
| US20030109466A1 (en) | 2001-09-20 | 2003-06-12 | Isis Pharmaceuticals Inc. | Antisense modulation of KSR expression |
| US7301017B2 (en) * | 2002-05-30 | 2007-11-27 | Kolesnick Richard N | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| US7528116B2 (en) * | 2002-05-30 | 2009-05-05 | Memorial Sloan Kettering Cancer Center | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20040265961A1 (en) * | 2003-03-28 | 2004-12-30 | Wei Liu | Novel proteins homologous to kinase suppressor of Ras |
-
2003
- 2003-12-03 US US10/727,358 patent/US7301017B2/en not_active Expired - Fee Related
-
2004
- 2004-12-03 AU AU2004297594A patent/AU2004297594B2/en not_active Ceased
- 2004-12-03 AT AT04812928T patent/ATE457351T1/de not_active IP Right Cessation
- 2004-12-03 JP JP2006542782A patent/JP4855265B2/ja not_active Expired - Fee Related
- 2004-12-03 WO PCT/US2004/040506 patent/WO2005056756A2/en not_active Ceased
- 2004-12-03 CA CA002549384A patent/CA2549384A1/en not_active Abandoned
- 2004-12-03 DE DE602004025499T patent/DE602004025499D1/de not_active Expired - Lifetime
- 2004-12-03 EP EP04812928A patent/EP1697498B1/en not_active Expired - Lifetime
-
2007
- 2007-10-12 US US11/974,473 patent/US8258108B2/en not_active Expired - Fee Related
- 2007-10-12 US US11/974,481 patent/US8283459B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Long noncoding RNAs and tumorigenesis: genetic associations, molecular mechanisms, and therapeutic strategies | |
| Lang et al. | SMAD3/SP1 complex‐mediated constitutive active loop between lncRNA PCAT7 and TGF‐β signaling promotes prostate cancer bone metastasis | |
| JP2005534295A5 (https=) | ||
| Shetty et al. | Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells | |
| Lawrence et al. | A concerted DNA methylation/histone methylation switch regulates rRNA gene dosage control and nucleolar dominance | |
| Ohta et al. | The FHIT gene, spanning the chromosome 3p14. 2 fragile site and renal carcinoma–associated t (3; 8) breakpoint, is abnormal in digestive tract cancers | |
| Liu et al. | Roles of lncRNA in breast cancer | |
| US20190062740A1 (en) | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS | |
| JP2008532477A5 (https=) | ||
| CA2488404A1 (en) | Genes and polypeptides relating to human colon cancers | |
| Arunkumar | LncRNAs: the good, the bad, and the unknown | |
| JP2005522225A (ja) | 亢進された遺伝子発現系 | |
| JP2012501164A5 (https=) | ||
| JP2007512844A5 (https=) | ||
| JP2003530090A (ja) | ヒトｃｈｋ１遺伝子のアンチセンスオリゴヌクレオチドおよびその用途 | |
| Corcoran et al. | DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse | |
| JP2005537007A5 (https=) | ||
| Berner et al. | Deregulation of mitochondrial gene expression in cancer: Mechanisms and therapeutic opportunities | |
| Tsukamoto et al. | Differential expression in glioblastoma multiforme and cerebral hemangioblastoma of cytoplasmic proteins that bind two different domains within the 3'-untranslated region of the human glucose transporter 1 (GLUT1) messenger RNA. | |
| US20060252684A1 (en) | Osteopontin-based cancer therapies | |
| Wardrop et al. | Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene | |
| Zeng et al. | Exon/intron structure and alternative transcripts of the CUTL1 gene | |
| Rodrigues et al. | Leptin receptor expression and Gln223Arg polymorphism as prognostic markers in oral and oropharyngeal cancer | |
| Yamashita et al. | Identification of cis-elements of the human endothelin-A receptor gene and inhibition of the gene expression by the decoy strategy | |
| Ubeda et al. | CHOP/GADD153 and methionyl-tRNA synthetase (MetRS) genes overlap in a conserved region that controls mRNA stability |